Table 1.
Clinical data of patients
| Patient | Gender/age | Disease duration (years) | RF | ESR (mm/h) | CRP (mg/ml) | ARA | Concurrent medication |
|---|---|---|---|---|---|---|---|
| EB87 |
F/65 |
12 |
+ |
50 |
106.7 |
5 |
NSAIDs |
| EB88 |
F/62 |
10 |
+ |
90 |
169.5 |
6 |
NSAIDs |
| EB213 |
F/69 |
15 |
+ |
94 |
99.1 |
4 |
NSAIDs, leflunomide, prednisone |
| EB220 |
F/57 |
20 |
+ |
23 |
2.3 |
4 |
NSAIDy, prednisone, MTX |
| EB221 |
F/66 |
12 |
+ |
7 |
5.4 |
4 |
NSAIDs, MTX |
| EB227 |
F/49 |
25 |
+ |
12 |
2.4 |
5 |
Celecoxib, prednisone, MTX, leflunomide |
| EB253 |
F/53 |
19 |
+ |
38 |
40.1 |
5 |
Azufildine |
| EB261 |
F/54 |
23 |
+ |
18 |
8.2 |
4 |
Prednisone, MTX, alendronate |
| EB266 |
F/63 |
11 |
+ |
35 |
17.4 |
5 |
NSAIDs, prednisone, azathioprin |
| EB268 | F/53 | 8 | + | 25 | 14.8 | 6 | NSAIDs, MTX, etanercept (TNF-blocker) |
ARA, number of American Rheumatism Association (now ACR) RA classification criteria; CRP, C-reactive protein (normal range < 5 mg/l); ESR, erythrocyte sedimentation rate; F, female; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; RF, rheumatoid factor; +, positive.